Selected dietary supplements labelled to contain Acacia rigidula have been found to be adulterated with the amphetamine isomer ?-methylphenylethylamine (BMPEA).
Selecte
Photo Credit: FotografiaBasica/Getty Images
d dietary supplements labelled to contain Acacia rigidula have been found to be adulterated with the amphetamine isomer β-methylphenylethylamine (BMPEA).1 This is not, however, a new finding. In 2014 the U.S. Food and Drug Administration (FDA) published on the detection of BMPEA in Acacia rigidula dietary supplements, but failed to warn consumers of the potential danger from the adulterant.2
The compound BMPEA was first synthesized in the early 1930s as a substitute for amphetamines, but, until recently, was treated as a research chemical. It is not found naturally in Acacia rigidula, but is added as an additional (often unlisted) ingredient for its physiological effects even though it has not been evaluated for safety in humans. Dr. Pieter Cohen of Harvard Medical School in Massachusetts, USA, told The Column: “We were aware of the FDA findings and mystified that they had not warned consumers or clarified the legality of these spiked products. We were interested to know what would manufacturers do once the FDA had discovered the stimulant.”
The authors purchased 21 dietary supplements labelled as containing Acacia rigidula online in the USA in 2014, and performed liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analyses. The paper reports that more than half of the samples were adulterated with BMPEA ranging from 8.4% to 31.8% per serving. Although only a small number of supplements were analyzed, making it impossible to know if the BMPEA adulteration is a limited issue, it is concerning that the FDA have not exercised their regulatory power to force manufacturers to remove BMPEA.
In a press release published in response to the study by the Council for Responsible Nutrition,3 Steve Mister, president & CEO, said: “Given FDA’s earlier findings combined with this new study by Dr. Cohen, we urge FDA to take immediate enforcement action against these adulterated products containing BMPEA and the companies illegally spiking these products with this synthetic drug. BMPEA does not appear to be a legitimate dietary ingredient, and therefore its inclusion in a product labelled as a dietary supplement makes the product adulterated under the Dietary Supplement Health & Education Act (DSHEA).” - B.D.
References
1. P.A. Cohen, C. Bloszies, and R. Gerona, Drug Testing and Analysis DOI 10.1002/dta.1793 (2015).
2. R.S. Pawar, E. Grundel, A.R. Fardin-Kia, and J.I. Rader, Journal of Pharmaceutical and Biomedical Analysis88, 457-466 (2014) doi:10.1016/j.jpba.2013.09.012.
3. Council for Responsible Nutrition: Press Release “CRN Asks FDA to Enforce the Law” (Last Accessed 10 April 2015: http://www.crnusa.org/CRNPR15-AsksFDAtoEnforcetheLaw040715.html)
New Study Uses MSPE with GC–MS to Analyze PFCAs in Water
January 20th 2025Scientists from the China University of Sciences combined magnetic solid-phase extraction (MSPE) with gas chromatography–mass spectrometry (GC–MS) to analyze perfluoro carboxylic acids (PFCAs) in different water environments.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.